Left ventricular diastolic dysfunction in systemic sclerosis : Clinical, immunological and survival differences in the Spanish RESCLE registry
Copyright © 2022. Published by Elsevier Inc..
OBJECTIVES: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc.
METHODS: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival.
RESULTS: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death.
CONCLUSIONS: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Seminars in arthritis and rheumatism - 55(2022) vom: 15. Aug., Seite 152033 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.07.2022 Date Revised 01.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semarthrit.2022.152033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342128752 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342128752 | ||
| 003 | DE-627 | ||
| 005 | 20231226013357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semarthrit.2022.152033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342128752 | ||
| 035 | |a (NLM)35691226 | ||
| 035 | |a (PII)S0049-0172(22)00084-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a González García, Andrés |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Left ventricular diastolic dysfunction in systemic sclerosis |b Clinical, immunological and survival differences in the Spanish RESCLE registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2022 | ||
| 500 | |a Date Revised 01.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a OBJECTIVES: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc | ||
| 520 | |a METHODS: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival | ||
| 520 | |a RESULTS: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death | ||
| 520 | |a CONCLUSIONS: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anticentromere | |
| 650 | 4 | |a Antinuclear antibodies, Diffuse scleroderma, Limited scleroderma | |
| 650 | 4 | |a Interstitial pneumonia | |
| 650 | 4 | |a Pulmonary hypertension | |
| 650 | 4 | |a Systemic sclerosis | |
| 700 | 1 | |a Fabregate, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Manzano, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Guillén Del Castillo, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio Rivas, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Argibay, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Marín Ballvé, Adela |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Pintó, Ignasi |e verfasserin |4 aut | |
| 700 | 1 | |a Pla Salas, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Marí-Alfonso, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Callejas Moraga, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Colunga Argüelles, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Sáez Comet, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a González-Echávarri, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ortego-Centeno, Norberto |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas Hitos, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Todolí Parra, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Trapiella Martínez, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Herranz Marín, María Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Freire, Mayka |e verfasserin |4 aut | |
| 700 | 1 | |a Chamorro, Antonio-J |e verfasserin |4 aut | |
| 700 | 1 | |a Perales Fraile, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Madroñero Vuelta, Ana Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Trigo, Sabela |e verfasserin |4 aut | |
| 700 | 1 | |a Tolosa Vilella, Carles |e verfasserin |4 aut | |
| 700 | 1 | |a Fonollosa Pla, Vicent |e verfasserin |4 aut | |
| 700 | 1 | |a Simeón Aznar, Carmen Pilar |e verfasserin |4 aut | |
| 700 | 0 | |a RESCLE Investigators, Systemic Autoimmune Diseases Study Group (GEAS) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in arthritis and rheumatism |d 1971 |g 55(2022) vom: 15. Aug., Seite 152033 |w (DE-627)NLM000215643 |x 1532-866X |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2022 |g day:15 |g month:08 |g pages:152033 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semarthrit.2022.152033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2022 |b 15 |c 08 |h 152033 | ||